22,356 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Purchased by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio bought a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 22,356 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,491,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in JAZZ. Itau Unibanco Holding S.A. acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at about $29,000. EverSource Wealth Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Jazz Pharmaceuticals by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 121 shares during the last quarter. Venturi Wealth Management LLC increased its position in Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 704 shares in the last quarter. Finally, Blue Trust Inc. lifted its stake in Jazz Pharmaceuticals by 24.5% in the 2nd quarter. Blue Trust Inc. now owns 1,307 shares of the specialty pharmaceutical company’s stock valued at $139,000 after purchasing an additional 257 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bruce C. Cozadd sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the sale, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. The trade was a 0.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,753 shares of company stock worth $816,289 in the last quarter. Company insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on JAZZ shares. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. TD Cowen reduced their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Needham & Company LLC restated a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $177.00.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $122.49 on Wednesday. The firm has a market cap of $7.41 billion, a PE ratio of 17.29, a price-to-earnings-growth ratio of 1.02 and a beta of 0.57. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The business’s 50 day moving average price is $117.72 and its two-hundred day moving average price is $112.36.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.